去纤维钠适合什么人用？

(Defibrotide, defiteli) is an injection drug that has not yet been launched in my country. Many people in the country are not familiar with it. Today we will take a closer look at what kind of people are defibrinated sodium suitable for? How to use it?

Defibrotide sodium is a single-stranded oligonucleotide mixture with anti-thrombotic and fibrinolytic effects. It is suitable for adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Corbacioglu et al. analyzed the value of defibrinated sodium in the treatment of HVOD in children in a retrospective clinical study. The study included 45 patients with HVOD after HSCT who were <20 years old, with a median age of 8.2 years (0.2-20 years). The dosage of defibrinated sodium is 10~110 mg/kg per day, intravenous infusion, and the median use time is 17 days (1-83 days). The results showed that the complete response (CR) rate was 76%, and the overall survival (OS) rate 1,00 days after transplantation was 64%. Among them, the CR rate of 22 SHVOD patients was 50%, and the OS rate 100 days after transplantation was 36%. This study not only confirmed the effectiveness of defibrotide sodium in the treatment of HVOD in children, but also showed that the addition of other drugs for the treatment of HVOD does not affect the efficacy of defibrotide sodium in the treatment of HVOD.

Let’s take a look at how to use fiber-reduced sodium.

The recommended dose of defibrotide (defiteli) is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. Treatment lasts for a minimum of 21 days. If the signs and symptoms of VOD do not resolve after 21 days, continue treatment until resolution.

(Defibrinoside, defiteli) may enhance the pharmacodynamic activity of antithrombotic/fibrinolytic agents such as heparin or alteplase. Concomitant use with antithrombotic or fibrinolytic agents is contraindicated due to increased risk of bleeding. Do not initiate defibrination in patients with active bleeding. Monitor patients for signs of bleeding.